PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy                Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes               Gdańsk, Poland – 16 January 2024, 07:00 CET – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide...